Skip to main content

Table 2 p503S, p504S and p510S positive cells in peripheral blood of patients with prostate cancer (CaP) in relation to Gleason score and TNM stage.

From: Can p503s, p504s and p510s gene expression in peripheral-blood be useful as a marker of prostatic cancer?

  P503S+ P504S+ P510S+
Group 1 (treated CaP) No No No
Total (n = 11) patients (%) patients (%) patients (%)
subtype 1 without recurrence (n = 5) 2 (40) 2 (40) 5 (100)
subtype 2 with recurrence (n = 6) 5 (83) 5 (83) 6 (100)
Gleason score    
4–7 (n = 9) 4 (44.44) 6 (66.66) 9 (100)
8 (n = 2) 2 (100) 2 (100) 2 (100)
TNM    
Organ-confined disease (n = 7)    
T2 N0 M0 (n = 7) 4 (57.14) 5 (71.42) 7 (100)
Extraprostatic disease (n = 4)    
T3 N0 M0 (n = 2) 1 (50) 1 (50) 2 (100)
T3 N1M0 and T3 N2M0 (n = 2) 2 (100) 1 (50) 2 (100)
Group 2 (untreated CaP)    
Total (n = 11)    
Gleason score    
6–7 (n = 11) 2 (18.18) 9 (81.81) 11 (100)
TNM    
Organ-confined disease (n = 11)    
T1 (n = 4) 0 3 (75 4 (100)
T2 (n = 7) 2 (28.6) 6 (85.7) 7 (100)